bioAffinity Technologies Secures Australian Patent Expanding Global Lung Health Portfolio

Australian patent strengthens global patent portfolio -bioAffinity Technologies, Inc. a biotechnology company advancing early-stage diagnostic...

October 30, 2025 | Thursday | News
Avance Clinical Launches CNS Center of Excellence to Advance Global Biotech Trials

Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced th...

October 29, 2025 | Wednesday | News
Gelteq Initiates Preclinical Trial with Monash University to Advance Oral Delivery of Oily and Poorly Soluble Drugs

Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...

October 24, 2025 | Friday | News
Propanc Biopharma Enters Strategic $100M Financing Agreement with Hexstone Capital

Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing agreement of up to $100 million wit...

October 16, 2025 | Thursday | News
Immutep’s Phase III TACTI-004 Trial Surpasses 170 Patients Enrolled, On Track for Futility Analysis in Early 2026

Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the...

October 13, 2025 | Monday | News
Gelteq Partners with Melbourne Health to Develop Innovative Oral Gel Product for Bowel Polyp Prevention

Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...

October 10, 2025 | Friday | News
Eisai and Biogen Gain Australian Approval for LEQEMBI® in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved LEQEMBI® (lecanemab), a humanized...

September 25, 2025 | Thursday | News
Australia’s Immutep and GW Cancer Center Launch Phase II Trial of Efti in Early-Stage HR+/HER2-Negative Breast Cancer

GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER...

September 23, 2025 | Tuesday | News
Novotech and CTTQ Pharma Secure World’s First Approval of Anlotinib-Chemotherapy Combo for Advanced Soft Tissue Sarcoma

-Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Grou...

August 29, 2025 | Friday | News
Clearside Biomedical Secures Health Canada Approval for XIPERE® in Treating Uveitic Macular Oedema

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

July 25, 2025 | Friday | News
Everlab Raises US$10 Million to Scale AI-Driven Preventive Health Platform Globally

Everlab, the AI-powered health platform reimagining preventive care, announced a US$10 million (AU$15 million) seed round led by global growth equity fir...

July 22, 2025 | Tuesday | News
Gelteq Partners with IDT Australia to Establish Dedicated Manufacturing Facility for Global Gel-Based Therapeutics

Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white ...

July 21, 2025 | Monday | News
Imugene Reports 75% Overall Response Rate in U.S.–Australia Phase 1b Trial of Off-the-Shelf CAR T Therapy for Relapsed DLBCL

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall R...

July 15, 2025 | Tuesday | News
Liquid Instruments Partners with Scanfil to Onshore Moku Platform Production in Australia

Scanfil and Liquid Instruments have signed a manufacturing outsourcing agreement for Scanfil’s Melbourne plant in Australia. This agreement support...

June 26, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close